Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 4, 2009, Pages 386-387

  Pregun, Istvan ^a   Gergics, Peter ^a   Dabasi, Gabriella ^a   Igaz, Peter ^a   Racz, Karoly ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE;

ADULT; ANAMNESIS; ARTICLE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER INJURY; METASTASIS; PRIORITY JOURNAL; STOMACH CARCINOID; AUTOIMMUNE DISEASE; BLOOD; CARCINOID; GASTRITIS; IMMUNOLOGY; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; STOMACH TUMOR;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CHROMOGRANIN A; FEMALE; GASTRITIS, ATROPHIC; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; OCTREOTIDE; REMISSION INDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; AUTOIMMUNE DISEASES; GASTRITIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67649589541     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328315520d     Document Type: Article

References (10)

1. Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg 2006; 43:383-450. Review.
2. Sanduleanu S, De Bruine A, Stridberg M, Jonkers D, Biemond I, Hameeteman W, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Investig 2001; 31:802-811.
3. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152:443-448.
4. De Block C, Colpin G, Thielemans K, Coopmans W, Bogers JJ, Pelckmans PA, et al. Neuroendocrine tumour markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care 2004; 27:1387-1393.
5. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case control study. Aliment Pharmacol Ther 1999; 13:145-153.
6. Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mârdh S, Seensalu R. Omeprazole and CYP2C19 polymorphism: effects of long term treatment on serum gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 2000; 14:1495-1502.
7. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32:198-202.
8. Sondenaa K, Sen J, Heinle F, Fjetland L, Gudlaugsson E, Syversen U. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004; 28:890-895.
9. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scan J Gastroenterol 2004; 10:969-973.
10. Kölby L, Bernhardt P, Sward C, Johanson V, Ahlman H, Forssell-Aronsson E, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004; 120:269-273.